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Objective: In the 7th tumor, node, metastasis (TNM) classification, 
visceral pleural invasion (VPI) is defined as invasion beyond the elas-
tic layer, including invasion to the visceral pleural surface, and T1 
tumors with VPI are upgraded to T2a. To validate this, we analyzed 
the survival of non–small-cell lung cancer patients from a nationwide 
database and evaluated the prognostic impact of VPI.
Methods: The clinicopathological characteristics and prognosis of 
4995 patients who were included in the registry study of the Japanese 
Joint Committee of Lung Cancer Registry were retrospectively ana-
lyzed with a special interest in the prognostic impact of VPI. These 
patients underwent surgery in 2004 and were pathologically staged 
as T1a-3N0. VPI was defined as including PL1 and PL2 according 
to the 7th TNM Classification, but the Japanese Joint Committee of 
Lung Cancer Registry did not collect data regarding staining or how 
extensively VPI was evaluated in each participating institution.
Results: The survival differences were statistically significant 
between PL0 and PL1, PL1 and PL2, as well as PL2 and T3. There 
were no significant survival differences between T1a with VPI and 
T1b without VPI, or between T1a with VPI and T2a without VPI. 
There were no significant survival differences between T1b with VPI 
and T2a without VPI, or between T1b with VPI and T2b without VPI. 
There were no significant survival differences between T2a with VPI 
and T2b without VPI, or between T2b with VPI and T2b without VPI. 
T3 showed significantly worse prognosis than T2a with VPI and T2b 
with VPI.
Conclusions: In addition to the current TNM classification recom-
mendations, in which T1 tumors with VPI are upgraded to T2a, T2a 
tumors with VPI should be classified as T2b.
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(J Thorac Oncol. 2013;8:606-611)
Visceral pleural invasion (VPI) of lung cancer has been known to be a poor prognostic factor.1–10 In the 7th edi-
tion of the tumor, node, metastasis (TNM) classification for 
lung cancer, pleural invasion status is classified as follows: 
PL0, tumor within the subpleural lung parenchyma or super-
ficial invasion into the pleural connective tissue beneath the 
elastic layer; PL1, tumor invasion beyond the elastic layer; 
PL2, tumor invasion to the pleural surface; and PL3, tumor 
invasion into any part of the parietal pleura.11,12 Although the 
current TNM classification does not describe a survival dif-
ference between PL1 and PL211,12, VPI is defined to include 
PL1 and PL2. Tumors of 3 cm or less (T1a and T1b) with 
VPI (PL1 and PL2) are upgraded to T2a, whereas tumors 
greater than 3 and 7 cm or less (T2a and T2b) with VPI remain 
unchanged as T2.13 These recommendations—to upgrade the 
T-classification according to VPI status—were based on the 
results of five retrospective studies1–3,8,14 and not on the large-
scale data accumulated by the International Association for 
the Study of Lung Cancer (IASLC) Lung Cancer Project.11
In 2009, 253 Japanese institutions submitted information 
to the Japanese Joint Committee of Lung Cancer Registry 
(JJCLCR) regarding the outcome and clinicopathologic profiles 
of patients who had undergone surgical resection for primary 
lung cancer in the year 2004.15 We retrospectively analyzed the 
survival of almost 5000 patients with pulmonary non–small-
cell lung cancer (NSCLC) without node involvement from this 
registration to evaluate the impact of VPI on survival, and we 
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propose incorporating VPI into T-status classification in the 
forthcoming TNM classification of the Union for International 
Cancer Control (UICC) staging system.
PATIENTS AND METHODS
Patient Cohort
As described previously, the JJCLCR performed a 
nationwide retrospective registry study in 2010 on the out-
come and clinicopathologic profiles of resected primary lung 
neoplasms in Japan.15 Only primary lung cancers that had 
been resected in 2004 at certified teaching hospitals in Japan, 
with a follow-up period of at least 5 years, were considered 
eligible for the registration. The committee received the reg-
istered data of 11,663 patients from 253 teaching hospitals. 
The registry questionnaire included the following items: (1) 
demographic background, (a) date of registry, (b) sex, (c) birth 
month and year, and (d) date of diagnosis; (2) preoperative 
status, (a) Eastern Cooperative Oncology Group performance 
status, (b) preoperative comorbidity, (c) smoking status, and 
(d) status of serum tumor markers (CEA, SCC or CYFRA, 
SLX and NSE, or Pro-GRP); (3) clinical T factors, (a) tumor 
size, (b) extent of invasion to the main bronchus, (c) pleural 
invasion, (d) intrapulmonary metastasis, (e) status of pleural 
effusion, (f) extent of atelectasis, and (g) status of invaded 
organ; (4) clinical N factor (status of removal of and metas-
tasis to each lymph node); (5) clinical M factor (metastasized 
organ); (6) type of surgery, (a) induction therapy, (b) extent of 
lung resection, (c) place of tumor origin, (d) extent of lymph 
node removal, (e) gross curative status, (f) status of residual 
tumor, (g) lavage cytology findings, and (h) combined resec-
tion; (7) postoperative morbidity; (8) tumor histology; (9) 
adjuvant therapy; (10) pathological T factors, (a) tumor size, 
(b) extent of bronchial involvement, (c) pleural invasion, (d) 
intrapulmonary metastasis, (e) status of pleural effusion, (f) 
pleural dissemination, (g) status of atelectasis, and (h) status 
of invaded organ; (11) pathological N factor (status of removal 
of and metastasis to each lymph node); and (12) pathologi-
cal M factor (metastasized organ). The extent of resection 
(exploratory, R0, R1, or R2) was also registered. Although the 
Japan Lung Cancer Society also recommends using not only 
hematoxylin and eosin (HE) staining but also elastic staining 
such as Victoria-blue van Gieson staining in VPI evaluation, 
the JJCLCR did not collect data regarding staining or how 
extensively VPI was evaluated in each participating institu-
tion. Diseases were staged based on the 7th edition of the 
UICC TNM classification.11,12 Histopathologic classifications 
were described according to World Health Organization crite-
ria.16 Recurrent or multiple lung cancers were not included in 
the registration.
Of the 11,663 patients, 4995 patients (42.8%) under-
went pulmonary resection (lobectomy or greater) and sys-
tematic mediastinal lymph node dissection for pathologically 
T1aN0, T1bN0, T2aN0, T2bN0, or T3N0 NSCLC. All these 
patients had curative resection, which was defined as complete 
removal of the ipsilateral hilar and mediastinal lymph nodes 
together with the complete resection of the primary tumor. 
Patients who had induction chemotherapy, radiotherapy, or 
both, and patients with evidence of residual tumor at the surgi-
cal margin, malignant effusion, interlobar invasion, or distant 
metastasis, verified intraoperatively or by means of postopera-
tive pathologic examination were excluded from this study.
Statistical Analysis
Pleural invasion status was classified according to the 
7th edition of the UICC TNM classification11–13: PL0, tumor 
within the subpleural lung parenchyma or superficial invasion 
into the pleural connective tissue beneath the elastic layer; 
PL1, tumor invasion beyond the elastic layer; PL2, tumor 
invasion to the pleural surface; and PL3, tumor invasion into 
any part of the parietal pleura. In the following descriptions, 
T-classification is determined excluding VPI status, but PL3 
tumors are classified as T3.
First, we analyzed the overall survival of PL0, PL1 and 
PL2 or T3 patient groups. Second, defining VPI to include 
PL1 and PL2, we analyzed the overall survival of the pT1a 
patient groups with or without VPI, pT1b with or without 
VPI, pT2a with or without VPI, and pT2b with or without VPI 
or T3. The follow-up period was defined as the time from the 
date of surgery to the most recent follow-up examination. The 
survival period was defined as the number of months from the 
day of surgery to the day of death from any cause. Survival 
curves were estimated using the Kaplan-Meier method. 
Differences in survival were tested using the log-rank test. 
A p value of less than 0.05 was considered to indicate a sta-
tistically significant difference. All statistical analyses were 
performed using software packages (SAS version 9.1.3 [SAS 
Institute, Inc., Cary, NC], SPSS version 19 [IBM Corp., New 
York, NY]).
This study was approved by the institutional review 
board of Osaka University Medical Hospital, where the office 
of JJCLCR is located, on August 13, 2009 (approval no. 09124).
RESULTS
Patient Characteristics and 
Visceral Pleural Invasion
Table 1 shows the patient characteristics. There were 
2981 men and 2014 women, aged 15 to 90 years (median, 
67 years). The extent of pulmonary resection was pneumo-
nectomy (n = 65), bilobectomy (n = 122), and lobectomy 
(n = 4808). The histological types were adenocarcinoma 
(n = 3638), squamous cell carcinoma (n = 1028), adenosqua-
mous carcinoma (n = 84), large-cell carcinoma (n = 149), and 
other histological types (n = 96).
Survival Differences
The overall 5-year survival rates for PL0 (n = 3606), 
PL1 (n = 727), PL2 (n = 219), and T3 (n = 443) patients 
were 87%, 77%, 69%, and 54%, respectively. There were 
significant survival differences between PL0 and PL1 (p < 
0.001), between PL1 and PL2 (p = 0.023), and between PL2 
and T3 (p < 0.001) patients (Fig. 1).
The survival curves stratified by T and VPI status are 
shown in Figure 2A. Figure 2B shows the survival impact of 
VPI on T1a tumors. Although T1a tumors with VPI had a 
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significantly poorer prognosis than T1a tumors without VPI 
(p < 0.001), there were no significant survival differences 
between T1a tumors with VPI and T1b tumors without VPI 
(p = 0.083) or T2a tumors without VPI (p = 0.221).
Figure 2C shows the survival impact of VPI on T1b 
tumors. Although T1b tumors with VPI had a significantly 
poorer prognosis than T1b tumors without VPI (p = 0.001), 
there were no significant survival differences between T1b 
TABLE 1.  Patient Characteristics
No. of Patients (%)
VPI Factor of T1/T2 Cases
Characteristics PL0 PL1 PL2 T3 Total
Age, yr
 Median (range) 67 (15–89) 68 (31–90) 68 (30–85) 69 (34–83) 67 (15–90)
Sex
 Men 2034 (56) 466 (64) 142 (64) 339 (77) 2981 (60)
 Women 1572 (44) 261 (36) 77 (36) 104 (23) 2014 (40)
Surgery
 Lobectomy 3477 (96) 706 (97) 215 (98) 410 (93) 4808 (96)
 Bilobectomy 95 (3) 12 (2) 3 (1) 12 (3) 122 (2)
 Pneumonectomy 34 (1) 9 (1) 1 (1) 21 (5) 65 (1)
Histology
 Adenocarcinoma 2743 (76) 505 (70) 168 (77) 222 (50) 3638 (73)
 Squamous cell carcinoma 660 (18) 168 (23) 37 (17) 163 (37) 1028 (21)
 Adenosquamous carcinoma 55 (2) 14 (2) 2 (1) 13 (3) 84 (2)
 Large-cell carcinoma 81 (2) 32 (4) 7 (3) 29 (7) 149 (3)
 Others 67 (2) 8 (1) 5 (2) 16 (4) 96 (2)
Tumor diameter, cm
 <2 1558 (43) 199 (27) 40 (18) 29 (7) 1826 (37)
 2.1–3 1125 (31) 215 (30) 72 (33) 71 (16) 1483 (30)
 3.1–5 805 (22) 252 (35) 81 (37) 130 (29) 1268 (25)
 5.1–7 118 (3) 61 (8) 26 (12) 72 (16) 277 (6)
 ≥7.1– – – – 141 (32) 141 (3)
Total 3606 727 219 443 4995
VPI status was defined according to the 7th edition of the tumor, node, metastasis classification for lung and pleural tumors.
VPI, visceral pleural invasion
FIGURE 1.  Overall survival curves of PL0, 
PL1, PL2, and T3 patients.
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tumors with VPI and T2a tumors without VPI (p = 0.823) or 
T2b tumors without VPI (p = 0.124).
Figure 2D shows the survival impact of VPI on T2a 
tumors. T2a tumors with VPI had a significantly poorer 
prognosis than T2a tumors without VPI (p < 0.001). There 
were no significant survival differences between T2a tumors 
with VPI and T2b tumors without VPI (p = 0.483). T2a tumors 
with VPI had a significantly better prognosis than T3 tumors 
(p < 0.001).
Figure 2E shows the survival impact of VPI on T2b 
tumors. There were no significant survival differences between 
T2b tumors with VPI and T2b tumors without VPI (p = 0.926). 
T2b tumors with VPI had a significantly better prognosis than 
T3 tumors (p = 0.005).
FIGURE 2. (A) Survival curves stratified by T stage and VPI status. (B) Survival curves of T1a/VPI–, T1b/VPI–, T2a/VPI–, and T1a/
VPI+. (C) Survival curves of T1b/VPI–, T2a/VPI–, T2b/VPI–, and T1b/VPI+. (D) Survival curves of T2a/VPI–, T2b/VPI–, T2b/VPI–, 
and T2a/VPI+.(E) Survival curves of T2b/VPI–, T3, and T2b/VPI+.
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DISCUSSION
VPI is known to be a poor prognostic factor of NSCLC 
patients and is defined as a factor to upgrade T1a/T1b tumors to 
T2a in the 7th Edition of the TNM Classification for Lung and 
Pleural Tumours.11,12,14 Travis et al.13,17,18 recommend the use of 
elastic stains when invasion beyond the elastic layer is not clear 
on evaluation of HE sections. Although the Japan Lung Cancer 
Society also recommends using not only HE staining, but also 
elastic staining such as Victoria-blue van Gieson staining in VPI 
evaluation, the JJCLCR did not collect data regarding staining 
or how extensively VPI was evaluated in each participating 
institution. This is a major limitation of the present study.
In the present study, PL1 patients had a significantly 
poorer prognosis than PL0 patients, consistent with many pre-
vious reports.1–10 PL2 patients had a significantly poorer prog-
nosis than PL1 patients. The survival difference between PL1 
and PL2 patients remains controversial. Kawase et al.10 ana-
lyzed a cohort of more than 2700 patients, using the current 
VPI definition and elastic staining in all cases for VPI diagno-
sis, and reported no survival differences between PL1 and PL2 
patients. Moreover, several other researchers have reported 
similar results.2,6,9 In contrast, Sakakura et al. 4 reported signifi-
cant differences in survival between PL1 and PL2 patients, but 
they did not describe whether or not they used elastic stains 
in diagnosing VPI status. In the data of the JJCLCR registry, 
it is not clear in what portion of the accumulated cases elastic 
staining was employed, and there remains some uncertainty 
regarding the determination of pleura invasion. Some PL0 
patients might have been miscategorized as PL1 without the 
use of elastic staining, which may have led to the significant 
survival difference observed between PL1 and PL2 patients. 
To conclude whether or not a difference between PL1 and PL2 
survival is valid, it is necessary to study more patients with 
VPI diagnoses made with the help of elastic staining.
To analyze the prognostic impact of VPI on T-status clas-
sification in the current cohort, we defined VPI to include PL1 
and PL2 patients, as defined by the 7th edition of the TNM 
Classification for Lung and Pleural Tumours. T1a with VPI 
had a significantly poorer prognosis than T1a without VPI, 
but there were no significant survival differences between T1a 
with VPI and T1b without VPI, or between T1a with VPI and 
T2a without VPI. To summarize, T1a with VPI had prognosis 
similar to that of T1b/T2a without VPI, which suggests it is 
credible to upgrade T1a with VPI to T2a.
T1b with VPI had a significantly poorer prognosis 
than T1b without VPI, but there were no significant survival 
differences between T1b with VPI and T2a without VPI or 
between T1b with VPI and T2b without VPI. To summarize, 
T1b with VPI had a similar prognosis to T2a/T2b without 
VPI, which suggests it is reasonable to upgrade T1b with 
VPI to T2a, as described in the 7th edition of the TNM 
Classification for lung cancer.11,12
The most significant information of the present study is 
the outcome of T2a with VPI. T2a with VPI had a significantly 
poorer prognosis than T2a without VPI. There were no significant 
survival differences between T2a with VPI and T2b without VPI. 
T2a with VPI had a significantly better prognosis than T3. To 
summarize, T2a with VPI had a similar prognosis to T2b without 
VPI, which suggests T2a with VPI should be upgraded to T2b.
In the current cohort, there were no significant survival 
differences between T2b with VPI and T2b without VPI. T2b 
with VPI had a significantly better prognosis than T3. To sum-
marize, T2b with VPI had a prognosis similar to that of T2b 
without VPI, which suggests there is no need to upgrade T2b 
with VPI. These suggestions are summarized in Table 2, and 
they include some differences from the conclusions of previ-
ous publications.2,8,10
A major limitation of the current study is that we do not 
know how thoroughly VPI was evaluated including elastic stain-
ing, in each participating institution. The differences observed 
may have been attributable to misdiagnoses of VPI status due to 
the lack of elastic staining use. However, the recommendation 
of the 7th edition of the TNM classification, that is, to upgrade 
T-classification according to VPI status, was determined on 
the basis of the results of some retrospective studies of small 
cohorts, in contrast to the large number cohort accumulated by 
the IASLC Lung Cancer Project. Moreover, the IASLC Lung 
Cancer Project also lacks detailed information on VPI status 
evaluation methodology. Therefore, we consider that a world-
wide large-scale study that is limited to patients whose VPI sta-
tus is diagnosed using elastic staining is necessary to determine 
the true impact on survival of pleural invasion and VPI.
In conclusion, in addition to the current TNM Classification 
recommendations—to upgrade tumors of 3 cm or less with VPI to 
T2a—tumors greater than 3 cm and 5 cm or less with VPI should 
be upgraded to T2b. However, more detailed further research is 
necessary for the next edition of the TNM classification for lung 
and pleural tumours, using a large-scale database with VPI status 
diagnosed using elastic staining. 
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TABLE 2.  T-Classification Comparison
Tumor Diameter, cm VPI Ctatus
7th Edition
T-Classification Our Proposal
<2 − T1a T1a
<2 + T2a T2a (or T1b)
2.1–3 − T1b T1b
2.1–3 + T2a T2a
3.1–5 − T2a T2a
3.1–5 + T2a T2b
5.1–7 − T2b T2b
5.1–7 + T2b T2b
VPI– = PL0, VPI+ = PL1 or PL2.
VPI, visceral pleural invasion.
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